Spots Global Cancer Trial Database for letrozole
Every month we try and update this database with for letrozole cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | NCT04300790 | Breast Cancer | Alpelisib Metformin Fulvestrant Letrozole Exemestane Vildagliptin Tamoxifen | 18 Years - | MedSIR | |
| Endometrial Preparation by Short Course of Letrozole Before Hysteroscopic Removal of Endocavitary Lesions | NCT04364581 | Myoma;Uterus | Letrozole Placebo | 18 Years - 45 Years | Mansoura University | |
| Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | NCT01153672 | Male Breast Can... Recurrent Breas... Stage IV Breast... | vorinostat laboratory biom... biopsy F-18 16 alpha-f... positron emissi... anastrozole letrozole exemestane gene expression... | 18 Years - | University of Washington | |
| Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer | NCT02228681 | Advanced, Persi... | Everolimus Tamoxifen Letrozole Medroxyprogeste... | 18 Years - | GOG Foundation | |
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
| Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy | NCT00688194 | Breast Cancer | anastrozole exemestane fulvestrant lapatinib ditos... letrozole placebo | 18 Years - | National Cancer Institute (NCI) | |
| Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer | NCT03936270 | Ovarian Cancer | Palbociclib 125... Letrozole 2.5mg | 18 Years - | Latin American Cooperative Oncology Group | |
| Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer | NCT00549822 | Breast Cancer | Letrozole | 18 Years - | Massachusetts General Hospital | |
| Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | NCT04852081 | Breast Cancer S... | Palbociclib Ribociclib Abemaciclib Letrozole Anastrozole Tamoxifen Fulvestrant Exemestane Alpelisib | 18 Years - | Blokhin's Russian Cancer Research Center | |
| Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment | NCT00237198 | Postmenopausal ... | Letrozole | 20 Years - 79 Years | Novartis | |
| Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density | NCT00114270 | Breast Cancer Osteoporosis | letrozole zoledronic acid | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery | NCT00305825 | Breast Cancer | bevacizumab letrozole | 18 Years - 120 Years | University of California, San Francisco | |
| Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer | NCT04191382 | Breast Cancer | Amcenestrant (S... Letrozole | 18 Years - | Sanofi | |
| Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy | NCT04137640 | Breast Cancer | palbociclib com... epirubicin comb... | 18 Years - 70 Years | Shengjing Hospital | |
| Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions | NCT01367626 | Breast Cancer | letrozole letrozole | 18 Years - 45 Years | West-Ward Pharmaceutical | |
| Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer | NCT00237211 | Postmenopausal ... | Letrozole | 20 Years - 74 Years | Novartis | |
| Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer | NCT04272801 | Breast Cancer F... | tamoxifen, letr... Patient reporte... | 65 Years - | University of Virginia | |
| Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer | NCT02228681 | Advanced, Persi... | Everolimus Tamoxifen Letrozole Medroxyprogeste... | 18 Years - | GOG Foundation | |
| Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) | NCT01908556 | is to Identify ... | Letrozole | 18 Years - | Institut fuer Frauengesundheit | |
| Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole | NCT05163106 | Breast Cancer HER2-negative B... ER-positive Bre... Locally Advance... Luminal A Breas... Luminal B Breas... | Letrozole 2.5mg... Goserelin | 18 Years - | University Hospital, Akershus | |
| A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer | NCT02296801 | Breast Cancer Breast Carcinom... Breast Tumors | Letrozole palbociclib | 18 Years - | NSABP Foundation Inc | |
| Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects | NCT02538484 | Breast Cancer | Letrozole Fish Oil | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer | NCT00880009 | Breast Cancer | Bosutinib Letrozole Letrozole | 18 Years - | Pfizer | |
| Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer | NCT02228681 | Advanced, Persi... | Everolimus Tamoxifen Letrozole Medroxyprogeste... | 18 Years - | GOG Foundation | |
| Study of PF-07248144 in Advanced or Metastatic Solid Tumors | NCT04606446 | Locally Advance... Locally Advance... Locally Advance... | PF-07248144 Fulvestrant Letrozole Palbociclib PF-07220060 | 18 Years - | Pfizer | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | NCT02947685 | HER-2 Positive ... Estrogen Recept... | palbociclib trastuzumab pertuzumab letrozole Anastrozole Exemestane Fulvestrant | 18 Years - | Alliance Foundation Trials, LLC. | |
| Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Poly Cystic Ovary Syndrome ( PCOS ) | NCT02551367 | Anovulation Polycystic Ovar... | Letrozole Clomiphene citr... hcg hormone | 20 Years - 35 Years | Ain Shams Maternity Hospital | |
| To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy | NCT02549430 | Breast Cancer | Palbociclib Anastrozole Letrozole Exemestane Fulvestrant | 18 Years - | Fondazione Sandro Pitigliani | |
| Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors | NCT01758146 | Breast Cancer | Tamoxifen Letrozole | 45 Years - 80 Years | PGIMER | |
| Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC | NCT00134680 | Metastatic Brea... | Letrozole Trastuzumab | 18 Years - | Duke University | |
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | NCT04557449 | Liposarcoma CRC Prostate Cancer Breast Neoplasm... Adenocarcinoma ... Solid Tumors | PF-07220060 Letrozole Fulvestrant Midazolam Enzalutamide | 18 Years - | Pfizer | |
| Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | NCT01231659 | Postmenopausal ... Locally Advance... Metastatic Brea... | Everolimus Letrozole | 18 Years - | Novartis | |
| A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma | NCT01797523 | Endometrial Can... | Metformin Letrozole Everolimus | 18 Years - | M.D. Anderson Cancer Center | |
| A Window-of-opportunity Study of Pelareorep in Early Breast Cancer | NCT04102618 | Breast Cancer | Pelareorep Letrozole Atezolizumab Trastuzumab | 18 Years - | Oncolytics Biotech | |
| Letrozole Versus Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome | NCT03009838 | Infertility | Letrozole ovarian drillin... | 20 Years - 35 Years | Assiut University | |
| Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC | NCT05228951 | Breast Cancer | Pyrotinib malea... | 18 Years - 75 Years | Shengjing Hospital | |
| Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer | NCT02910050 | Breast Cancer | Bicalutamide Aromatase Inhib... | 18 Years - 80 Years | Sun Yat-sen University | |
| A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer | NCT05909397 | Breast Cancer | ARV-471 (PF-078... Palbociclib Letrozole Palbociclib | 18 Years - | Pfizer | |
| Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer | NCT00601900 | Invasive Breast... Recurrent Breas... Stage III Breas... Stage IV Breast... | Bevacizumab Laboratory Biom... Letrozole Questionnaire A... Tamoxifen Citra... | 18 Years - | National Cancer Institute (NCI) | |
| Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer | NCT02619669 | Breast Cancer | TAK-228 Letrozole | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy | NCT00999804 | Breast Cancer | Lapatinib Letrozole Trastuzumab | 18 Years - | Baylor Breast Care Center | |
| A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | NCT06394804 | Low-Grade Serou... | Avutometinib Defactinib Letrozole | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer | NCT01698918 | Hormone Recepto... | Everolimus Letrozole Exemestane Alcohol-free de... Standard of car... | 18 Years - | Novartis | |
| Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome. | NCT02304107 | Infertility | FSH Letrozole | 20 Years - 40 Years | Cairo University | |
| Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity | NCT04630210 | Breast Cancer | Letrozole Atezolizumab | 18 Years - 75 Years | Universitaire Ziekenhuizen KU Leuven | |
| Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer | NCT00280930 | Post-Menopausal Breast Cancer | Letrozole | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer | NCT00171704 | Hormone Sensiti... | Letrozole Tamoxifen | 50 Years - | Novartis | |
| Aromatase Inhibitor Clinical Trial | NCT00228956 | Breast Cancer | pharmacodynamic... | 40 Years - 70 Years | National Institute of General Medical Sciences (NIGMS) | |
| Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy | NCT03220178 | Breast Neoplasm | Palbociclib Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Palleos Healthcare GmbH | |
| Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls | NCT02450175 | Neoplasm | Everolimus Letrozole | 18 Years - | Sinai Hospital of Baltimore | |
| Polycystic Ovary Syndrome (PCOS): Effect Of Letrozole and Berberine | NCT01116167 | Polycystic Ovar... | Letrozole -Berb... Letrozole Berberine | 20 Years - 40 Years | Heilongjiang University of Chinese Medicine | |
| Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer. | NCT00611715 | Breast Cancer | erlotinib hydro... letrozole fluorescence in... immunohistochem... laboratory biom... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | NCT06016738 | Breast Cancer Advanced Breast... Metastatic Brea... ER Positive Bre... HER2 Negative B... | Palazestrant Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Olema Pharmaceuticals, Inc. | |
| Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer | NCT03900884 | Breast Neoplasm... | Venetoclax Palbociclib Letrozole | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls | NCT02450175 | Neoplasm | Everolimus Letrozole | 18 Years - | Sinai Hospital of Baltimore | |
| Study to Compare Between Combimed Metformin-letrozole and Ovarian Drilling in Pcos With Bilateral Ovarian Drilling in Clomiphene-resistant Infertile Women With Polycystic Ovarian Syndrome | NCT01693289 | Focus of Study | metformin plus ... ovarian drillin... | 18 Years - 35 Years | Zagazig University | |
| A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix | NCT02482740 | Uterine Cervica... | Letrozole tamoxifen | 30 Years - 85 Years | Buddhist Tzu Chi General Hospital | |
| Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer | NCT06361940 | Breast Cancer | Aromatase inhib... | 18 Years - | Medical College of Wisconsin | |
| Letrozole Versus Hormonal Preparation in Frozen Cycles of PCOS Patients. | NCT05168865 | Frozen Embryo T... Polycystic Ovar... Letrozole Hormone Replace... Live Birth Miscarriage | Letrozole 2.5mg | 20 Years - 40 Years | Dubai Fertility Center | |
| Study of PF-07248144 in Advanced or Metastatic Solid Tumors | NCT04606446 | Locally Advance... Locally Advance... Locally Advance... | PF-07248144 Fulvestrant Letrozole Palbociclib PF-07220060 | 18 Years - | Pfizer | |
| Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer | NCT00073528 | Breast Neoplasm... | Lapatinib Letrozole Placebo | 18 Years - | Novartis | |
| Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not | NCT01553903 | Breast Cancer | Tamoxifen, Exemestane Anastrozole Letrozole | 18 Years - | Institut Claudius Regaud | |
| Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation | NCT05206448 | Polycystic Ovar... PCOS Infertility | Letrozole Clomiphene Citr... | 18 Years - 40 Years | University of Iowa | |
| Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | NCT05467891 | Locoregional Re... Hormone Recepto... HER2-negative B... | Ribociclib Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Hoosier Cancer Research Network | |
| The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS) | NCT01577017 | Polycystic Ovar... | Letrozole | 19 Years - 39 Years | Universiti Sains Malaysia | |
| Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer | NCT03774472 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... | Hydroxychloroqu... Letrozole Palbociclib | 18 Years - | M.D. Anderson Cancer Center | |
| Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms | NCT01194440 | Ductal Carcinom... Estrogen Recept... Progesterone Re... Stage I Breast ... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | letrozole zoledronic acid | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer | NCT05183828 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Breast Adenocar... Invasive Breast... | Biospecimen Col... Letrozole Questionnaire A... | 18 Years - | University of Washington | |
| Letrozole in Patients With Ovarian Tumors | NCT00505661 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Letrozole | 18 Years - | M.D. Anderson Cancer Center | |
| Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer | NCT00329940 | Breast Cancer | Letrozole | 18 Years - | Novartis | |
| Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer | NCT06361940 | Breast Cancer | Aromatase inhib... | 18 Years - | Medical College of Wisconsin | |
| Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome | NCT03135301 | Infertility, Fe... | letrozole plus ... letrozole | - | Assiut University | |
| Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer | NCT00687648 | Breast Cancer | anastrozole cyclophosphamid... exemestane letrozole methotrexate prednisolone | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery | NCT00305825 | Breast Cancer | bevacizumab letrozole | 18 Years - 120 Years | University of California, San Francisco | |
| Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer | NCT03936270 | Ovarian Cancer | Palbociclib 125... Letrozole 2.5mg | 18 Years - | Latin American Cooperative Oncology Group | |
| Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer | NCT00014638 | Breast Cancer | letrozole | 18 Years - | Novartis | |
| S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | NCT01674140 | Breast Cancer | anastrozole everolimus exemestane goserelin aceta... letrozole leuprolide acet... tamoxifen citra... placebo | 18 Years - | SWOG Cancer Research Network | |
| Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer | NCT04047758 | Breast Cancer | Palbociclib + L... Letrozole | 18 Years - 70 Years | Shengjing Hospital | |
| Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer | NCT01368263 | Estrogen Recept... HER2-negative B... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | goserelin aceta... letrozole anastrozole chemotherapy Surgery | 18 Years - | Washington University School of Medicine | |
| Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer | NCT04047758 | Breast Cancer | Palbociclib + L... Letrozole | 18 Years - 70 Years | Shengjing Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
